The deal provides no near-term capital for Imunon. Monitor VoxelDox's ability to close the $2.5 million financing, as the transaction collapses without it. Imunon's stock will trade on the progress of its IMNN-001 Phase 3 trial.
Price Chart
Executive Summary
Imunon entered into an asset purchase agreement to sell its ThermoDox program to VoxelDox Therapeutics. The deal is contingent on VoxelDox raising at least $2.5 million; if it closes, Imunon will receive a 4.76% equity stake, up to $16.5 million in milestone payments, and tiered royalties. The transaction allows Imunon to focus on its lead IMNN-001 program but provides no near-term cash and highly contingent future value.
Key Facts
- Imunon entered into an Asset Purchase Agreement to sell ThermoDox assets to VoxelDox Therapeutics on October 20, 2026.
- Transaction is contingent on VoxelDox raising at least $2.5 million; if not raised, the deal will not close and Imunon receives no consideration.
- If closed, Imunon receives 4.76% equity in VoxelDox, up to $16.5 million in milestone payments, and tiered royalties of 3.5% to 6% on net sales.
- ThermoDox is a legacy asset that has been fully written off, per the company's CEO statement.
- Imunon will focus resources on its lead program IMNN-001 (Phase 3 OVATION 3 trial for ovarian cancer).
Financial Impact
No upfront cash consideration. Potential future value of up to $16.5 million in milestones plus equity and royalties, all contingent on VoxelDox's success in financing and development.
Risk Factors
- Transaction may not close if VoxelDox fails to raise the required $2.5 million.
- Milestone and royalty payments are highly contingent on VoxelDox's clinical and regulatory success, with no assurance of value realization.
- If ThermoDox vials are deemed not usable, milestone payments and royalty rates are reduced by 50%.
- Imunon receives no upfront cash, so the deal does not address near-term cash needs.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-047850 |
| Exhibit: ex99-1.htm | 0001493152-26-047850 |
| Document: 0001493152-26-047850-index-headers.html | 0001493152-26-047850 |
| Document: 0001493152-26-047850-index.html | 0001493152-26-047850 |
| Document: 0001493152-26-047850.txt | 0001493152-26-047850 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 8-K | — | awaiting T+5 | — | — |
Oct 21, 2026 5d ago | 8-K | $1.19 | awaiting T+5 | — | $1.23 (+3.36%) |
Sep 29, 2026 27d ago | 8-K | $1.34 $1.12 | ▲ +16.10% | ▲ +18.05% | $1.23 (+7.87%) |
Aug 11, 2026 10w ago | 8-K | $1.61 $1.58 | ▼ −1.86% | ▼ −1.42% | $1.23 (−23.60%) |
Aug 11, 2026 10w ago | 8-K | $1.61 $1.58 | ▼ −1.86% | ▼ −1.46% | $1.23 (−23.60%) |
Jun 30, 2026 16w ago | 8-K | $1.88 $1.95 | ▲ +3.72% | ▲ +3.46% | $1.23 (−34.57%) |
Jun 16, 2026 18w ago | 8-K | $1.86 $1.73 | ▼ −6.99% | ▼ −5.95% | $1.23 (−33.87%) |
Jun 4, 2026 20w ago | 8-K | $2.10 $2.03 | ▲ +3.33% | ▲ +0.78% | $1.23 (+41.43%) |
May 12, 2026 23w ago | 8-K | $2.70 $2.26 | ▼ −16.30% | ▼ −16.37% | $1.23 (−54.44%) |
May 4, 2026 25w ago | 8-K | $2.80 $2.73 | ▼ −2.50% | ▼ −5.44% | $1.23 (−56.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers